-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 A3JyAXeWtS6NxpStNSJfOx+jrwmXYDUdG3u9PXgt4YNeJPKR3SjvwTW91h48IsH5
 ph7EfrtPzmIII1xVFE1ebw==

<SEC-DOCUMENT>0001144204-07-056279.txt : 20071025
<SEC-HEADER>0001144204-07-056279.hdr.sgml : 20071025
<ACCEPTANCE-DATETIME>20071025132643
ACCESSION NUMBER:		0001144204-07-056279
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20071025
FILED AS OF DATE:		20071025
DATE AS OF CHANGE:		20071025

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		071190355

	BUSINESS ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
		BUSINESS PHONE:		972-8-930-4440

	MAIL ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v091359_6k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div>&#160;</div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="white">
            <td width="100%" style="border-bottom: black double;">&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 16pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16 </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      October 25, 2007</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman"><strong><u>XTL
      Biopharmaceuticals Ltd.</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>711
      Executive Blvd., Suite Q</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Valley
      Cottage, New York 10989</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x </font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      40-F
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o
</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      N/A</u></font></div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="white">
            <td width="100%" style="border-bottom: black double;">&#160;</td>
          </tr>

      </table>
    </div>
    <div align="center">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><img src="logo.jpg"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Incorporation
      by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated October 25,
      2007 is hereby incorporated by reference into the registration statement on
      Form
      F-3 (File No. 333-141529) filed by XTL Biopharmaceuticals Ltd. with the
      Securities and Exchange Commission on March 23, 2007.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
      Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to
      Institutional Investors</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Valley
      Cottage, New York, October 25, 2007 </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
      XTL
      Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) today announced
      that
      it has entered into definitive agreements with institutional investors relating
      to a private placement of an aggregate of $9.6 million in gross proceeds of
      ordinary shares, represented by American Depositary Receipts (ADRs). The lead
      investors in the transaction are Perceptive Life Sciences Fund, Quogue Capital
      LLC, SCO Capital Partners and Versant Capital.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer of XTL, commented, &#8220;We are very pleased to have
      consummated this financing with high-quality investors in the biotechnology
      sector in the U.S. Following this offering, we believe that we will have
      sufficient capital to execute our business plan and, more importantly, to reach
      what we believe could be a major value-enhancing milestone - the completion
      of
      our on-going randomized, placebo-controlled Phase IIb trial of Bicifadine in
      diabetic neuropathic pain.&#8221;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the securities purchase agreements, the Company will, following the closing,
      issue approximately 7.1 million ADRs, representing approximately 71 million
      ordinary shares. No warrants were issued in the transaction. XTL has agreed
      to
      register the ordinary shares and list the ADRs for trading on the Nasdaq Stock
      Market. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Closing
      of the transaction is conditional upon, among other things, the delisting of
      the
      Company's ordinary shares from the Official List of the United Kingdom Listing
      Authority, scheduled to take place at 8:00 am (London Time) on October 31,
      2007.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Punk,
      Ziegel &amp; Company, L.P. and Brean Murray, Carret &amp; Co., LLC acted as
      placement agents in the transaction. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
      XTL BIOPHARMACEUTICALS LTD.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      Biopharmaceuticals Ltd. (&#8220;XTL&#8221;) is engaged in the development of therapeutics
      for the treatment of neuropathic pain and hepatitis C. XTL is developing
      Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment
      of diabetic neuropathic pain. XTL is also developing several novel pre-clinical
      hepatitis C small molecule inhibitors. XTL also has an active in-licensing
      and
      acquisition program designed to identify and acquire additional drug candidates.
      XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges
      (NASDAQ: XTLB; LSE: XTL; TASE: XTL).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      offering was made only to accredited investors, as such term is defined in
      accordance with the Securities Act of 1933, as amended. The ordinary shares
      have
      not been registered under the Securities Act of 1933, or any state securities
      laws. Therefore, they may not be offered or sold in the United States absent
      registration under or exemption from the Securities Act of 1933 and any
      applicable state securities laws. This announcement is neither an offer to
      sell
      nor a solicitation of an offer to buy our ordinary shares or warrants to
      purchase ordinary shares.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      +1-(845)-267-0707 ext. 225</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Cautionary
      Statement</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Some
      of the statements included in this press release, particularly those
      anticipating future financial performance, the delisting of our ordinary shares
      from the Official List of the United Kingdom Listing Authority, the clinical
      and
      business prospects for our clinical compound Bicifadine, growth and operating
      strategies and similar matters, may be forward-looking statements that involve
      a
      number of risks and uncertainties. For those statements, we claim the protection
      of the safe harbor for forward-looking statements contained in the Private
      Securities Litigation Reform Act of 1995. Risk factors that could adversely
      affect our operations are identified from time to time in our reports filed
      with
      the Securities and Exchange Commission and the London Stock Exchange, including
      our annual report on Form 20-F filed with the Securities and Exchange Commission
      on March 23, 2007. Any forward-looking statements set forth in this press
      release speak only as of the date of this press release. We do not intend to
      update any of these forward-looking statements to reflect events or
      circumstances that occur after the date hereof. This press release and prior
      releases are available at http://www.xtlbio.com. The information in our website
      is not incorporated by reference into this press release and is included as
      an
      inactive textual reference only. </em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>XTL
              BIOPHARMACEUTICALS LTD.</strong></font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font size="2">Date: October 25, 2007</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/
              Ron
              Bentsur</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%"><font size="2">Ron
              Bentsur</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
                Executive Officer</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0V'17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`P-SHQ,#HR
M-2`Q,3HR,CHR-P```````Z`!``,````!``$``*`"``0````!````JZ`#``0`
M```!````20`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```Q1````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`1`"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]55?J&;1T_!R,[()%.+6ZZR-3M8"]VW^
M5HN?^OV#UFWI)S^C9>1CY6#NLLIH>YHMJ_PK=C?I75;?4I_ZY7_A%YMTKZW=
M1;EM;UC-OSNDY3'8^=3:]SAZ%PV675_NVT_SOL]_^#4N/"9QX@=MX_I,<\@B
M0"-]B[#?\;?76YOVBW$Q_L$R[%;N]4,_DY&[:ZYK?^!]->J8V15E8U652=U5
M[&V5GQ:\;V_]$KS(_P"*>QESK<CJM7[&8/4?>&GUC2!O=W^SM_1_]J/^N^DN
M?ZK]<NKY&;;;TW,R,'IS`*L+%I>YC6TUCTZ?9_I;&C>]2RQ0R5[="AJL$Y0!
M]S6SH^Y)+SKJ-7UBZ)_B^NS<WJ.4>K9-E-CW&QQ=2USV-;C5_N?H_P"?_P"$
M7$_\Z/K/_P"6N;_VX],CRYE9$AH:7RRB-6#J^]I+P3_G1]9__+;,_P"W7)O^
M='UG_P#+7-_[<>G?=)?O!9]XCV+[XDO`_P#G1]9__+;,'QM</RKMO\5O5^K=
M0ZAU!F?FWY;*ZJRQMSR\-)<_<6[DV?+RC$R)!I=',)2X:+Z,DD@9SG-PLAS"
M6N;4\M<.00TZA0@6:9":!/9.DN4^HN=FY?VW[5D67[!5L]1Q=$BS=MW?O0NK
M3LN,XYF!-U6WBQ\OF&;%'(`0)7H?ZIX5))+E_K75]8;,RH]).0*A4=_HOVMW
M;N_N;[]J6.''(1XA'QELG-E]N!D(RG_5A\SU"2BV=HGF!*DF,BDDDDE/_]#U
M5>+?7WZL_L'K!?CLCIV>768\<,?S?B_CZM/_``7_`!2]I7+?XR+.E-^JU[.H
M`N>]S1@M;&_[3J:7,G\UGO\`7_[K^JI<$S&8K7BT(8\L1*)OIJ^=7?7#-M^I
M]7U;)=N99LLO_>Q&^ZG&F=V_?^B=_P!UJUI?XMOJN>J=2_:^6R<'I[_T33Q9
MD#5O_6\3^<_X_P!/_1V+C"'%I`,.C0^!7N/U'S>F9?U9P_V97Z%-#?1LQYDU
MVMUO8]WY[G/=ZWJ?X7U?55C.>"!X17$=2PX?7*Y&^$:!WDDDE2;3X+];/_%3
MU?\`\-/_`"-7K_U),_5+I/\`X5K_`.I7D'UL_P#%3U?_`,-/_(U>O_4G_P`2
M/2?_``K7^16N8_FX?RZ,&'YY_1Y?_'!_1.E_\=;_`-0U4?\`%!_RGU/_`(FK
M_JK%>_QP?T3I?_'6_P#4-5'_`!0?\I]3_P")J_ZJQ(?[F/\`+])!_G_H^HJO
MU#^@9/\`Q3_^I*L*OU#^@9/_`!3_`/J2JT?F'FS3^67D7@_JUUNCHV)FW/'J
M76^DVBD&-Q`LW.<[\UC-ROO^LGUO:#DNP=M$;M:+-H'B7;MZJ_4?!KR>INOM
M`<W$K#V`_P"D>=K'?V&ML7?J]S.3'#*?U8G(UQ&7E\L7,Y'%FR<O&LIQ1CQ"
M`@-_5K*;A_5_ZT4=7)HM:*,MHW!@,M>WNZEW\G\^M!^LWUER^C9-5-%-=K;:
MR\EY(((.W\U8/7JF]'^L[,C&'IL+J\AK1H!N)9<W^J_:_P#ST?Z__P!.Q?\`
MB7?]4E'!C.;&0/U>6)EPG]$@;*GS6:/+YHF59L$XP,Q^E&1TD]ID9-.+COR,
MEXKJJ&Y[SP`N2M^N/5<W(=3T;"W`:RYI>^/WWL86UT_VW*?U^S'MKQ<)I]C]
MUU@\=D-J'^<YSEN_5_IM73NETU-`]1[19>_NY[A+I_J_0:H81ACQ#)./'*9]
M$3\H$>K8R3RYN8EAQS]N&(`Y)Q^>4I;1B\\WZW==P+FLZOA#8[B&FMQ_XMSB
M^JS;^XNKP<[&S\5F5BOWU6#0]P1])CA^:]JCU/I]'4L*S$O$M>/:[NUP^A8W
M^4QRY+ZAY=E>=DX#S[7L]2.P?614_P#SVN_Z")CCRXI3C'@GCKB`^642B,\N
M#/#%DF<N/-8A*7SPG']%_]'U-[V,8Y[W!K&@ESB8``Y<XKP_ZY_69WUAZN_(
M8XCI^+NKPFGC;_A<DC]_(V_]L^FO0/\`&-D]=NP6]&Z/@Y&0W+$YF12PEHJF
M/LS7_P"DO=_._P#`?\:N1^I_U&ZGE];J=U?!MQ<#%BZP7-VBUS3^AQVS])N_
MWW?\%7Z?^$5G`(P!R2(OH&'+Q2(A'KN5LKZAY6/]2Z^MECOV@#]IR*-9;B.&
MC-G^FI;^LV?]=K_,53ZC?6;_`)O]8!O?'3<W;7E^#3_@,O\`ZU.VW_@/^+7M
M;FM<TM<`YKA!!U!![+QCZQ_47K'3^KWT=-P;\OI[SZF,^INX-8__`+3OU^E2
M[V?\7L3L>49!*&3KJ%L\9@8R@-M"^S@@B1J$ZY/_`!>Y?6QTP]+ZSAY&/;@@
M-Q[[F$"RD_S=>_\`TN/_`#?_`!7I+K%5E'A)&],X-BWP7ZV?^*GJ_P#X:?\`
MD:O7_J3_`.)'I/\`X5K_`"+S+ZS?5OZQ9'UCZI?C],R;:;<E[J[&5DM<T@0Y
MI_.7J/U1Q[\7ZL=,Q\FMU-]6.QME;Q#FN`U:YJLYR#CA1_E3#B!$YWU>3_QP
M?T3I?_'6_P#4-5'_`!0?\I=3_P")J_ZJQ:_^-/I?4^HXW3F]/Q+<MU=MAL%+
M=VT%K0W<O/C]5/K0?^\C+_[;/]Z=C$98>$R$;_BMGQ#+Q`7H^]2$#/UP<G_B
MG_\`4E>&?\T_K/\`^5&9_F'_`,DI5_5/ZSBVLGI.6`'M).P\`CS31R\00?<'
M\O\`"3++(@C@.SZ'_B^M8W(S*B?>^NM[1WAI>U__`)\8NV7GN!T/K]/J=0Q:
MK*,K%>"RI[8-C'#W^GN_G/W7U?G_`/&*\_ZV?61[30SIVS(.FX5V$@^+:G?]
M^>I.8P^[E,L<HG;BU^5I\ES/LX(PS0G`ZF'I,N,$_P#2:WUM/VSZRU8M6KVM
MII/]9[B__J;&HG^,#^G8W_$N_P"J5WZL_5S,;EGJW501=)=54\R_>[Z5]W\K
M_1L0OKMT[J&7FX[L3&LO:VIP<ZML@'=PGPG`9L4!($8HD&7Z/$1JQY<60\OG
MRF)$L\XRC#]*,(GT\2+_`!@4.]?$O'T7UOK^;2'_`/?EUO3<EF7T_'R*S+;*
MVNT\8]S?[+D+J_2J>K8+\2TEA,.JL`DL>/H/`_ZK^0N2Q;OK-]67.QSC?:,8
MDD`!SZY_?IMK]]6__1V,4,0,V&,`0,F,FA(UQQEV;,B>6YF>4Q,L.8"Y1'%[
M<X?O/<6VUTU/NL.VNMI<]Q[!HW.*X?ZCM?=UJ_)`A@J>YWQL>','_13YF=]9
M_K"T8=>&ZC'<?>`',:Z/]-?=M]G_``;%T_0.BU='P_2#O4OL.^^V(ET?1;_P
M;/S$J&##.,B#DR4.$&^&/]9%GF>8Q3C$C%AN7'(</',_HQ?_TO54DDDE*222
M24I))))2DDDDE*22224I))))2DDDDE*22224I))))2DDDDE/_]/U5)?*J22G
MZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27
MRJDDI^JDE\JI)*?JI)?*J22G_]G_[1)"4&AO=&]S:&]P(#,N,``X0DE-!"4`
M`````!``````````````````````.$))30/M```````0`$@````!``$`2```
M``$``3A"24T$)@``````#@`````````````_@```.$))300-```````$````
M>#A"24T$&0``````!````!XX0DE-`_,```````D```````````$`.$))300*
M```````!```X0DE-)Q````````H``0`````````".$))30/U``````!(`"]F
M9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&
M```````!`#4````!`"T````&```````!.$))30/X``````!P``#_________
M____________________`^@`````_____________________________P/H
M`````/____________________________\#Z`````#_________________
M____________`^@``#A"24T$`````````@`!.$))300"```````$`````#A"
M24T$"```````$`````$```)````"0``````X0DE-!!X```````0`````.$))
M300:``````-)````!@``````````````20```*L````*`%4`;@!T`&D`=`!L
M`&4`9``M`#$````!``````````````````````````$``````````````*L`
M``!)``````````````````````$`````````````````````````$`````$`
M``````!N=6QL`````@````9B;W5N9'-/8FIC`````0```````%)C=#$````$
M`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<`
M``!)`````%)G:'1L;VYG````JP````9S;&EC97-6;$QS`````4]B:F,````!
M```````%<VQI8V4````2````!W-L:6-E241L;VYG``````````=G<F]U<$E$
M;&]N9P`````````&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-875T
M;T=E;F5R871E9`````!4>7!E96YU;0````I%4VQI8V54>7!E`````$EM9R``
M```&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``
M````````3&5F=&QO;F<``````````$)T;VUL;VYG````20````!29VAT;&]N
M9P```*L````#=7)L5$585`````$```````!N=6QL5$585`````$```````!-
M<V=E5$585`````$```````9A;'1486=415A4`````0``````#F-E;&Q497AT
M27-(5$U,8F]O;`$````(8V5L;%1E>'1415A4`````0``````"6AO<GI!;&EG
M;F5N=6T````/15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L
M:6=N96YU;0````]%4VQI8V5697)T06QI9VX````'9&5F875L=`````MB9T-O
M;&]R5'EP965N=6T````115-L:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET
M;W!/=71S971L;VYG``````````IL969T3W5T<V5T;&]N9P`````````,8F]T
M=&]M3W5T<V5T;&]N9P`````````+<FEG:'1/=71S971L;VYG```````X0DE-
M!"@```````P````!/_`````````X0DE-!!0```````0````".$))300,````
M``QM`````0```*````!$```!X```?X````Q1`!@``?_8_^``$$I&248``0(!
M`$@`2```_^T`#$%D;V)E7T--``'_[@`.061O8F4`9(`````!_]L`A``,"`@(
M"0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1
M#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!$`*`#
M`2(``A$!`Q$!_]T`!``*_\0!/P```04!`0$!`0$``````````P`!`@0%!@<(
M"0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(
M!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/P
MX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U
M`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086
MHK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#U55^H9M'3\'(S
ML@D4XM;KK(U.U@+W;?Y6BY_Z_8/6;>DG/Z-EY&/E8.ZRRFA[FBVK_"MV-^E=
M5M]2G_KE?^$7FW2OK=U%N6UO6,V_.Z3E,=CYU-KW.'H7#99=7^[;3_.^SW_X
M-2X\)G'B!VWC^DQSR")`(WV+L-_QM]=;F_:+<3'^P3+L5N[U0S^3D;MKKFM_
MX'TUZIC9%65C595)W57L;96?%KQO;_T2O,C_`(I[&7.MR.JU?L9@]1]X:?6-
M(&]W?[.W]'_VH_Z[Z2Y_JOURZOD9MMO3<S(P>G,`JPL6E[F-;36/3I]G^EL:
M-[U++%#)7MT*&JP3E`'W-;.C[DDO.NHU?6+HG^+Z[-S>HY1ZMDV4V/<;'%U+
M7/8UN-7^Y^C_`)__`(1<3_SH^L__`):YO_;CTR/+F5D2&AI?+*(U8.K[VDO!
M/^='UG_\MLS_`+=<F_YT?6?_`,M<W_MQZ=]TE^\%GWB/8OOB2\#_`.='UG_\
MMLP?&UP_*NV_Q6]7ZMU#J'4&9^;?ELKJK+&W/+PTES]Q;N39\O*,3(D&ET<P
ME+AHOHR22!G.<W"R',):YM3RUPY!#3J%"!9ID)H$]DZ2Y3ZBYV;E_;?M619?
ML%6SU'%T2+-VW=^]"ZM.RXSCF8$W5;>+'R^89L4<@!`E>A_JGA4DDN7^M=7U
MALS*CTDY`J%1W^B_:W=N[^YOOVI8X<<A'B$?&6R<V7VX&0C*?]6'S/4)*+9V
MB>8$J28R*22224__T/55XM]??JS^P>L%^.R.G9Y=9CQPQ_-^+^/JT_\`!?\`
M%+VE<M_C(LZ4WZK7LZ@"Y[W-&"UL;_M.II<R?S6>_P!?_NOZJEP3,9BM>+0A
MCRQ$HF^FKYU=]<,VWZGU?5LEVYEFRR_][$;[J<:9W;]_Z)W_`'6K6E_BV^JY
MZIU+]KY;)P>GO_1-/%F0-6_];Q/YS_C_`$_]'8N,(<6D`PZ-#X%>X_4?-Z9E
M_5G#_9E?H4T-]&S'F37:W6]CW?GN<]WK>I_A?5]56,YX('A%<1U+#A]<KD;X
M1H'>2225)M/@OUL_\5/5_P#PT_\`(U>O_4DS]4ND_P#A6O\`ZE>0?6S_`,5/
M5_\`PT_\C5Z_]2?_`!(])_\`"M?Y%:YC^;A_+HP8?GG]'E_\<']$Z7_QUO\`
MU#51_P`4'_*?4_\`B:O^JL5[_'!_1.E_\=;_`-0U4?\`%!_RGU/_`(FK_JK$
MA_N8_P`OTD'^?^CZBJ_4/Z!D_P#%/_ZDJPJ_4/Z!D_\`%/\`^I*K1^8>;-/Y
M9>1>#^K76Z.C8F;<\>I=;Z3:*08W$"S<YSOS6,W*^_ZR?6]H.2[!VT1NUHLV
M@>)=NWJK]1\&O)ZFZ^T!S<2L/8#_`*1YVL=_8:VQ=^KW,Y,<,I_5B<C7$9>7
MRQ<SD<6;)R\:RG%&/$("`W]6LIN']7_K11U<FBUHHRVC<&`RU[>[J7?R?SZT
M'ZS?67+Z-DU4T4UVMMK+R7D@@@[?S5@]>J;T?ZSLR,8>FPNKR&M&@&XEES?Z
MK]K_`//1_K__`$[%_P")=_U24<&,YL9`_5Y8F7"?T2!LJ?-9H\OFB95FP3C`
MS'Z49'23VF1DTXN._(R7BNJH;GO/`"Y*WZX]5S<AU/1L+<!K+FE[X_?>QA;7
M3_;<I_7[,>VO%PFGV/W76#QV0VH?YSG.6[]7^FU=.Z734T#U'M%E[^[GN$NG
M^K]!JAA&&/$,DX\<IGT1/R@1ZMC)/+FYB6''/VX8@#DG'YY2EM&+SS?K=UW`
MN:SJ^$-CN(::W'_BW.+ZK-O[BZO!SL;/Q696*_?58-#W!'TF.'YKVJ/4^GT=
M2PK,2\2UX]KN[7#Z%C?Y3'+DOJ'EV5YV3@//M>SU([!]9%3_`//:[_H(F./+
MBE.,>">.N(#Y91*(SRX,\,629RX\UB$I?/"<?T7_T?4WO8QCGO<&L:"7.)@`
M#ESBO#_KG]9G?6'J[\ACB.GXNZO":>-O^%R2/W\C;_VSZ:]`_P`8V3UV[!;T
M;H^#D9#<L3F9%+"6BJ8^S-?_`*2]W\[_`,!_QJY'ZG_4;J>7UNIW5\&W%P,6
M+K!<W:+7-/Z'';/TF[_?=_P5?I_X16<`C`')(B^@8<O%(B$>NY6ROJ'E8_U+
MKZV6._:`/VG(HUEN(X:,V?Z:EOZS9_UVO\Q5/J-]9O\`F_U@&]\=-S=M>7X-
M/^`R_P#K4[;?^`_XM>UN:US2UP#FN$$'4$'LO&/K']1>L=/ZO?1TW!OR^GO/
MJ8SZF[@UC_\`M._7Z5+O9_Q>Q.QY1D$H9.NH6SQF!C*`VT+[."")&H3KD_\`
M%[E];'3#TOK.'D8]N"`W'ON80+*3_-U[_P#2X_\`-_\`%>DNL564>$D;TS@V
M+?!?K9_XJ>K_`/AI_P"1J]?^I/\`XD>D_P#A6O\`(O,OK-]6_K%D?6/JE^/T
MS)MIMR7NKL962US2!#FG\Y>H_5''OQ?JQTS'R:W4WU8[&V5O$.:X#5KFJSG(
M..%'^5,.($3G?5Y/_'!_1.E_\=;_`-0U4?\`%!_REU/_`(FK_JK%K_XT^E]3
MZCC=.;T_$MRW5VV&P4MW;06M#=R\^/U4^M!_[R,O_ML_WIV,1EAX3(1O^*V?
M$,O$!>C[U(0,_7!R?^*?_P!25X9_S3^L_P#Y49G^8?\`R2E7]4_K.+:R>DY8
M`>TD[#P"/--'+Q!!]P?R_P`),LLB".`[/H?^+ZUC<C,J)][ZZWM'>&E[7_\`
MGQB[9>>X'0^OT^IU#%JLHRL5X+*GM@V,</?Z>[^<_=?5^?\`\8KS_K9]9'M-
M#.G;,@Z;A782#XMJ=_WYZDYC#[N4RQRB=N+7Y6GR7,^S@C#-"<#J8>DRXP3_
M`-)K?6T_;/K+5BU:O:VFD_UGN+_^IL:B?XP/Z=C?\2[_`*I7?JS]7,QN6>K=
M5!%TEU53S+][OI7W?RO]&Q"^NW3NH9>;CNQ,:R]K:G!SJVR`=W"?"<!FQ0$@
M1BB09?H\1&K'EQ9#R^?*8D2SSC*,/THPB?3Q(O\`&!0[U\2\?1?6^OYM(?\`
M]^76]-R69?3\?(K,MLK:[3QCW-_LN0NK]*IZM@OQ+26$PZJP"2QX^@\#_JOY
M"Y+%N^LWU9<['.-]HQB20`'/KG]^FVOWU;_]'8Q0Q`S88P!`R8R:$C7'&79L
MR)Y;F9Y3$RPY@+E$<7MSA^\]Q;;734^ZP[:ZVESW'L&C<XKA_J.U]W6K\D"&
M"I[G?&QX<P?]%/F9WUG^L+1AUX;J,=Q]X`<QKH_TU]VWV?\`!L73]`Z+5T?#
M](.]2^P[[[8B71]%O_!L_,2H8,,XR(.3)0X0;X8_UD6>9YC%.,2,6&Y<<AP\
M<S^C%__2]522224I))))2DDDDE*22224I))))2DDDDE*22224I))))2DDDDE
M*22224__T_54E\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27
MRJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?_V0`X0DE-!"$`````
M`%,````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````2
M`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``0P!3`````0`X0DE-
M!`8```````<`!`````$!`/_A%_EH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C`O`#P_>'!A8VME="!B96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53
M>DY48WIK8SED)S\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TG861O8F4Z;G,Z;65T
M82\G('@Z>&UP=&L])UA-4"!T;V]L:VET(#,N,"TR."P@9G)A;65W;W)K(#$N
M-B<^"CQR9&8Z4D1&('AM;&YS.G)D9CTG:'1T<#HO+W=W=RYW,RYO<F<O,3DY
M.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R<@>&UL;G,Z:5@])VAT='`Z+R]N<RYA
M9&]B92YC;VTO:5@O,2XP+R<^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70])W5U:60Z96,R.&4R9F4M.#,P9"TQ,61C+6(W-#0M93@T9&)A,V5E,S`T
M)PH@('AM;&YS.F5X:68])VAT='`Z+R]N<RYA9&]B92YC;VTO97AI9B\Q+C`O
M)SX*("`\97AI9CI#;VQO<E-P86-E/C$\+V5X:68Z0V]L;W)3<&%C93X*("`\
M97AI9CI0:7AE;%A$:6UE;G-I;VX^,3<Q/"]E>&EF.E!I>&5L6$1I;65N<VEO
M;CX*("`\97AI9CI0:7AE;%E$:6UE;G-I;VX^-S,\+V5X:68Z4&EX96Q91&EM
M96YS:6]N/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70])W5U:60Z96,R.&4R9F4M.#,P9"TQ,61C+6(W-#0M93@T
M9&)A,V5E,S`T)PH@('AM;&YS.G!D9CTG:'1T<#HO+VYS+F%D;V)E+F-O;2]P
M9&8O,2XS+R<^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TG=75I9#IE8S(X93)F92TX,S!D+3$Q9&,M8C<T-"UE
M.#1D8F$S964S,#0G"B`@>&UL;G,Z<&AO=&]S:&]P/2=H='1P.B\O;G,N861O
M8F4N8V]M+W!H;W1O<VAO<"\Q+C`O)SX*("`\<&AO=&]S:&]P.DAI<W1O<GD^
M/"]P:&]T;W-H;W`Z2&ES=&]R>3X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.F5C,CAE,F9E+3@S,&0M
M,3%D8RUB-S0T+64X-&1B83-E93,P-"<*("!X;6QN<SIT:69F/2=H='1P.B\O
M;G,N861O8F4N8V]M+W1I9F8O,2XP+R<^"B`@/'1I9F8Z3W)I96YT871I;VX^
M,3PO=&EF9CI/<FEE;G1A=&EO;CX*("`\=&EF9CI84F5S;VQU=&EO;CXW,B\Q
M/"]T:69F.EA297-O;'5T:6]N/@H@(#QT:69F.EE297-O;'5T:6]N/C<R+S$\
M+W1I9F8Z65)E<V]L=71I;VX^"B`@/'1I9F8Z4F5S;VQU=&EO;E5N:70^,CPO
M=&EF9CI297-O;'5T:6]N56YI=#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.F5C,CAE,F9E+3@S,&0M
M,3%D8RUB-S0T+64X-&1B83-E93,P-"<*("!X;6QN<SIX87`])VAT='`Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\G/@H@(#QX87`Z0W)E871E1&%T93XR,#`W
M+3$P+3(U5#$Q.C(R.C(W+3`U.C`P/"]X87`Z0W)E871E1&%T93X*("`\>&%P
M.DUO9&EF>41A=&4^,C`P-RTQ,"TR-50Q,3HR,CHR-RTP-3HP,#PO>&%P.DUO
M9&EF>41A=&4^"B`@/'AA<#I-971A9&%T841A=&4^,C`P-RTQ,"TR-50Q,3HR
M,CHR-RTP-3HP,#PO>&%P.DUE=&%D871A1&%T93X*("`\>&%P.D-R96%T;W)4
M;V]L/D%D;V)E(%!H;W1O<VAO<"!#4R!7:6YD;W=S/"]X87`Z0W)E871O<E1O
M;VP^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TG=75I9#IE8S(X93)F92TX,S!D+3$Q9&,M8C<T-"UE.#1D8F$S
M964S,#0G"B`@>&UL;G,Z>&%P34T])VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]M;2\G/@H@(#QX87!-33I$;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H
M;W1O<VAO<#IE8S(X93)F9"TX,S!D+3$Q9&,M8C<T-"UE.#1D8F$S964S,#0\
M+WAA<$U-.D1O8W5M96YT240^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#IE8S(X93)F92TX,S!D+3$Q
M9&,M8C<T-"UE.#1D8F$S964S,#0G"B`@>&UL;G,Z9&,])VAT='`Z+R]P=7)L
M+F]R9R]D8R]E;&5M96YT<R\Q+C$O)SX*("`\9&,Z9F]R;6%T/FEM86=E+VIP
M96<\+V1C.F9O<FUA=#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*/"]R9&8Z4D1&
M/@H\+W@Z>&UP;65T83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"CP_>'!A8VME="!E;F0])W<G/S[_X@Q824-#7U!2
M3T9)3$4``0$```Q(3&EN;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A
M8W-P35-&5`````!)14,@<U)'0@``````````````````]M8``0````#3+4A0
M("``````````````````````````````````````````````````````````
M`````!%C<')T```!4````#-D97-C```!A````&QW='!T```!\````!1B:W!T
M```"!````!1R6%E:```"&````!1G6%E:```"+````!1B6%E:```"0````!1D
M;6YD```"5````'!D;61D```"Q````(AV=65D```#3````(9V:65W```#U```
M`"1L=6UI```#^````!1M96%S```$#````"1T96-H```$,`````QR5%)#```$
M/```"`QG5%)#```$/```"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H
M="`H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P``````
M```2<U)'0B!)14,V,3DV-BTR+C$``````````````!)S4D="($E%0S8Q.38V
M+3(N,0``````````````````````````````````````````````````````
M````````````6%E:(````````/-1``$````!%LQ865H@````````````````
M`````%A96B````````!OH@``./4```.06%E:(````````&*9``"WA0``&-I8
M65H@````````)*````^$``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W
M+FEE8RYC:```````````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````
M``````````````````````````````````````````````````````!D97-C
M`````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C
M92`M('-21T(``````````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="
M(&-O;&]U<B!S<&%C92`M('-21T(`````````````````````````````9&5S
M8P`````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q
M.38V+3(N,0``````````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO
M;B!I;B!)14,V,3DV-BTR+C$``````````````````````````````````'9I
M97<``````!.D_@`47RX`$,\4``/MS``$$PL``UR>`````5A96B```````$P)
M5@!0````5Q_G;65A<P`````````!`````````````````````````H\````"
M<VEG(`````!#4E0@8W5R=@````````0`````!0`*``\`%``9`!X`(P`H`"T`
M,@`W`#L`0`!%`$H`3P!4`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?
M`*0`J0"N`+(`MP"\`,$`Q@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!
M&0$?`24!*P$R`3@!/@%%`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q
M`;D!P0')`=$!V0'A`>D!\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$"
M>@*$`HX"F`*B`JP"M@+!`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F
M`W(#?@.*`Y8#H@.N`[H#QP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$
MC`2:!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075
M!>4%]@8&!A8&)P8W!D@&609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'
M80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0
M"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+
M"PLB"SD+40MI"X`+F`NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF
M#4`-6@UT#8X-J0W##=X-^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/
ME@^S#\\/[!`)$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F
M$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5
M$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;
M&$`891B*&*\8U1CZ&2`911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;
MBANR&]H<`APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3
M'SX?:1^4'[\?ZB`5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC
M"B,X(V8CE"/"(_`D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8
M)TDG>B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDK
MG2O1+`4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U
M,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U
M336'-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT
M.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`
M(T!D0*9`YT$I06I!K$'N0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>
M1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),
M*DQR3+I-`DU*39--W$XE3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\
M4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9
M:5FX6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!7
M8*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-G
MZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X
M;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9W
MLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E
M@$>`J($*@6N!S8(P@I*"](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(
MSHDSB9F)_HIDBLJ+,(N6B_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&H
MDA&2>I+CDTV3MI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;
M0INOG!R<B9SWG62=TIY`GJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'
MI3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O
M%J^+L`"P=;#JL6"QUK)+LL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*
MN<*Z.[JUNRZ[I[PAO)N]%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$
M4<3.Q4O%R,9&QL/'0<>_R#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\W
MS[C0.="ZT3S1OM(_TL'31-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:
M^]N`W`7<BMT0W9;>'-ZBWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6
MYQ_GJ>@RZ+SI1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS
M&?.G]#3TPO50]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M
M____[@`.061O8F4`9``````!_]L`A``&!`0$!00&!04&"08%!@D+"`8&"`L,
M"@H+"@H,$`P,#`P,#!`,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0<'
M!PT,#1@0$!@4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!)`*L#`1$``A$!`Q$!_]T`!``6_\0!
MH@````<!`0$!`0``````````!`4#`@8!``<("0H+`0`"`@,!`0$!`0``````
M```!``(#!`4&!P@)"@L0``(!`P,"!`(&!P,$`@8"<P$"`Q$$``4A$C%!4083
M82)Q@10RD:$'%;%"(\%2T>$S%F+P)'*"\25#-%.2HK)C<\(U1">3H[,V%U1D
M=,/2X@@F@PD*&!F$E$5&I+16TU4H&O+C\\34Y/1E=865I;7%U>7U9G:&EJ:V
MQM;F]C='5V=WAY>GM\?7Y_<X2%AH>(B8J+C(V.CX*3E)66EYB9FIN<G9Z?DJ
M.DI::GJ*FJJZRMKJ^A$``@(!`@,%!00%!@0(`P-M`0`"$0,$(1(Q0051$V$B
M!G&!D3*AL?`4P='A(T(54F)R\3,D-$."%I)3):)CLL('<](UXD2#%U23"`D*
M&!DF-D4:)V1T53?RH[/#*"G3X_.$E*2TQ-3D]&5UA96EM<75Y?5&5F9VAI:F
MML;6YO9'5V=WAY>GM\?7Y_<X2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ
M2EIJ>HJ:JKK*VNKZ_]H`#`,!``(1`Q$`/P#U3BK3ND:,[D*B@LS'H`-R<5?,
M7F3_`)RP\PKKTJZ!IMJ=&@D*1&YYF6=5-.9*E1'S_9%,VN/L\</J.[KIZVCM
MR>]_E[YVL?.GE2SU^SC,(N`4GMV-3%,AXNE>]#T/\N:_-B,)<)<[',2%AD>5
M,W8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J_P#_T.S_`)V_X[M/
M*;ZSY/U"2UN],K->6J(DGK6]/C(#JWQQ?;V^TO+,C3<!E4AS:<_%PW%\Z:!_
MSD-^8=OK%G/K.J-J6CAP-0LFBB420/\`#)0JJMR"GDN^;.>BA6PW=?#5RO?D
MFFJ_\XT^<;C41<^5IK34?+M]2?3[UYA&RP2_$GJ*022JGJG+ED8ZZ('JVD&4
MM&2;')OS9YYUG\L[>P\@>3]5XS:2'EU[441&$U[<$,T:APW%(1_LOYL&/",M
MSD.?TIRY3B`C%G/_`#C_`.8OS4\XZI<:OK>LRR>7-/!C](Q1(+BX8;)R5`>,
M0/)Z?M<<Q]7CQP%`>HMVFG.>YY/*M1_/K\UHM1NXH_,#K''/*B+Z4&RK(P`^
MQX#,P:/'7)QIZF8*''Y^_FV>GF%S_P`\H/\`FC#^2Q]S#\WD[W'\_?S;'7S"
M_P#R)@_YHQ_)8^Y?S>3O:_Y7]^;7_4PO_P`BH/\`FC'\EC[D_FLC?_*_?S;_
M`.I@D_Y$P?\`-&/Y+'W(_-S[WU=^4FM:GK?Y<:%JNJ3FYU"[MR]Q.0JEF]1A
M6B@+T&:C41$9D#D[7%(F()9=E+8QG\R-5U#2O*%[?:?,8+J(Q\)0`:<I%4[,
M".AS+T.*.3*(RY.N[6SSQ:>4X&I"O]TE_P"4NO:MK?ER:[U2X-S<+<O&KD*M
M%"J0/A`\<M[2P1QY`(BAPM'8FJR9\)E,\4N)FV:]W#L5>;_FUK_FS2[G34T&
M29%E24SB&+U!52O&IXM3J<VO9N'%/B\2MJZO/]MZK48C'P;WOBX8\3-_+EQ=
M7&@:=/=EC=2VT3SEAQ8NR`M4;4-<U^8`3D!RMW.EE*6*)E]1B.),<J;W8J[%
M78J__]'U0RJRE6`96%&4[@@]CBKXK_/3\M3Y*\WNUI&1H6JEKC3F`^&-JUE@
M_P">9-4_XKS>Z3/QQW^H.GU6'AE8Y,J_*_\`/G_#/Y9ZMHUXWJ:KIJT\N*U3
MS$YIP/\`DV[_`+S_`(Q_#E.?2<60$<C]3=AU50(/-Y1Y<T#7/./FFWTNT+3Z
MGJDQ::X?>G(\YIG]E')SF9.8A&^@<2$3DD^Z_*?E?2_+'EZRT+34X6EG&$!_
M:=CN\C>+NU6;.?R3,Y$EW<("(H)>_P"6'Y=N[._EO3F=R69C;QU)8U).W<Y+
MQI]Y8^%'N>,?\Y/^4?*VA^5]'FT?2;73YI;XI));Q)&S+Z+'B2H%149G:#)*
M4C9Z.)K(1$108!_SCGHVDZQ^9`LM5LX;ZT-C._H7""1.2E*-Q:HJ*YDZV9CC
MV/5Q]'$&6[ZE_P"57?ES_P!2UIW_`$C1_P!,U'CS[R[/PH]SXL_,2TM;/S[Y
MBM+6)(+:#4+F.&&,!41%D("J!T`S>X23`$]SILPJ9?7_`.1/_DH_+/\`S"G_
M`).OFEU7]X7;X/H#/,QVYAWYN?\`*!:C\X?^3JYG]F?W\?C]SJ.W?\4G_F_[
MH,/_`"W\X:/Y8\B376HN2\EY*+>WCH9)"$6M`:;#NQS/U^EGFS@1_FNI[(UV
M/3:4RF?XSPQ_BER5D_/^W,Y#:._H5V(F7G3Y<:9$]BGI+[&8]J(W]!KWL^\J
M^<]#\S6K3:=*?4BIZ]M(.,J5Z5'<?Y2YJ]3I9X34G>Z+7XM3&X'WQ_B0GG/S
M_IOE1[5;VWFG^MARAAX[>G2M>1'\V3TNCEFOA(]+5VAVG#2UQ`GC_FI_IM\E
M_I]M>HI1+F))D5NH$BA@#3OOF-.)C(@_PN=BR"<!(?Q#B8AYJ_-SRYH5R]G$
M'U"]C/&6.$@(A\&D.U?9>69^F[,R9!?TQ=5K>W,."7#]<_Z+';;\_K4R@76D
M2)$3]J.568#_`%2JU^_,J78LJVDZ^'M/&_5`@>]Z-Y=\S:-YAL?KFESB:,'C
M(A'%T;KQ=3N#FJSX)XI5(/0:75X\\>*!L)IE+DO_TO5.*L._-OR;I/FOR/J%
MCJ$B6QMXVNK6^DH!!+"I8.3V3]F3_(R[3Y#"8(:LT!*)!?"GW'W'3Z,Z%T1#
MZC_YQ1\N:!'Y<OO,,4J7&MW$S6MRM/BMHDW6/?\`W[_>,W[7P_R9J.T)RXA'
M^%VNC@!&^KWG->YKL5>$?\Y<_P#*(Z'_`-M$_P#)E\V'9WU'W.%KOI#S;_G%
MW_R:B_\`;/N?UIF5K_[OXN-HOK?8&:5VSX)_,_\`\F/YG_[:=U_R=.=#@^@>
MYT6?ZS[WUU^1/_DH_+/_`#"G_DZ^:;5?WA=O@^@,\S';F'?FY_R@6H_.'_DZ
MN9_9G]_'X_<ZCMW_`!2?^;_N@\V_*'R;9:]?W%[J<?KV-AQ6.W8_`\K[_$.X
M516F;;M35RQ@1C]4GG>P.SXYI&<_5#'_``_TGLUWY6\N7=JUK/IELT##CQ$2
M+0>Q`!'T9H(ZC)$V)&WL)Z/%*/"8QKW/#9HIO(/YD*EM(QM8Y4(J=WM9^JMX
M\?\`B2YT8D-5IM^?^_B\48G0:VHGTW_TKFR/\_2#)HI!J"DY!_X#,/L3^/\`
MS?TNP]J/\G_G?[U/_-'F2?0ORNT^2U?T[R[M;:V@<=5YQ`LP]U4;9C:;3C+J
M2#],92D[#6ZLX-#$CZI0A&/^E2'\GO(>GWMHWF#585N>3LEE#*.2?":-(P/V
MB6V6N9/:FMD)>'$U_.<#L'LR,X^-D'%?T<7^Z>G:IY7\OZI9O:7EA#)$PH*(
MJLONK`54CVS48]1.!L$V])FT>+)'AE$4\1TZ2]_+_P#,7ZGZI:S,BQ2UV$EM
M,?@9A_,E:_ZRYT62M5I[_B_W[QF$RT&LX+]!/^PD^@>2^/:OT>.<N]X__]/U
M3BKYT_YR@_,_B@\BZ5+\4@677)$/1/M1V^W\WVY/\GCFST&#^,_YK@:S-0X0
M\/T3R+YAUKRUK/F*QAYZ=H80W1WY-R/Q"/Q])?WDG^3FPEEC&0B><G"AA,HD
M]R>?DS^9$OD;S=%=3,3HM_QM]5C&X$9/PS`?S0DU_P!3GE6JP>)'^DSTN7@E
MY/MV&:*:))HG$D4BAXW4U#*PJ"#X$9H7<KL5>$?\Y<_\HCH?_;1/_)E\V'9W
MU'W.%KOI#S;_`)Q=_P#)J+_VS[G]:9E:_P#N_BXVB^M]@9I7;/@G\S__`"8_
MF?\`[:=U_P`G3G0X/H'N=%G^L^]]=?D3_P"2C\L_\PI_Y.OFFU7]X7;X/H#/
M,QVYAWYN?\H%J/SA_P"3JYG]F?W\?C]SJ.W?\4G_`)O^Z"2_D.J#RS?$'XC>
M'E]$:4S([8_O!_5</V9`\"7]?_>AZ7FH>C>"?G45?SO"B']Y]6A4TZU+M3.D
M[(VPGWO#^T.^I`_HA-/SU4JF@*>HAE!^8$>4]C<Y_#]+D>TW+'_G?[UK\TED
M/D+RF1_=B.,-\S;K3^.'L[^_R?C^)>VQ_@F'X?[AGOY6/$_D+2?3(/&-E:G\
MPD:N:WM$$9Y.]['(_*PKN_2RO,)V;P3\Z2C>>HE3[8MX`U/$L:?AG3=D[83[
MR\-[0[ZD`<^&+VOA)[_[R<?]EG/6/]D]CPG_`&#_`/_4[U^:GY@6?D;RE<ZM
M)Q>^D_<:;;$[R7#`\=OY$^V_^3EV#"<DJ:LN00C;XCABUOS+Y@6-2]]K6KW-
M.1W:2:9MR?;?_8KF^VA'RBZ;><GW-Y$\C:7Y4\FVOEN)%EB2(B]=A7UY91^^
M=AWYG;_4^'-!ERF<C)W>.`C&GQ]^;_Y?R^2/.EUIJ*?T7<UN=*D/0P.?[NOC
M$WP?\#FZTV;Q(WU=1J<7!)[7_P`XQ?F<=1TYO)>J2UO=/0R:5(YWDMA]J*O=
MH?V?^*_]3,'7X*/&.OU.;H\W$*+WO-<YKPC_`)RY_P"41T/_`+:)_P"3+YL.
MSOJ/N<+7?2'FW_.+O_DU%_[9]S^M,RM?_=_%QM%];[`S2NV?!7YG_P#DQ_,_
M_;3NO^3ISH<'T#W.BS_6?>RKRK_SD1YW\L^7K'0;"UL7L["/TH7E20N1R+?$
M0X'?PRK)HX2D26Z&KE$4FW_0UGYC?\L>G?\`(N7_`)KR'Y"'FR_/262_\Y`^
M=/-@&@:E;64=G>']Z\*.)!Z?QBA9V'5?#,C2:.$,@(MUW:VJE+32!\O]TSC\
MKO.\?EBYD@U-772-0/)9PI(26/X2VWVE_9>GV<N[1TGC"X_7!U/8G:(TQK)_
M=Y/XOZ3U>]_,_P`D6UHUR-4BGH*K##5Y&/@%I_Q+-)#L_-(UPT]5D[7TT8\7
M&#_5>5^7;6_\^_F&VJS1%+**5)[CNJ114]**O\S4_P")9NM1*.FT_`/J^G_B
MI/,:2$M=J_$(]$3Q?Z7Z8IW^?_\`?:-_JS_\:9C=B?Q_YOZ7+]J?\G_G?[UE
M&L>6'\Q_EG8V,-/K<=I;3VA/0R)$/A_V8JN86+4>%J3+IQ2XG:ZC1_F-'&`^
MK@C*'];A81^6'Y@0^6VGT+7@]O:B0F.1E),$IV='4;A2=_\`6S9]H:$Y:R8]
MS_NG2=C=IC3$X<WI%_Z63T75/S2\E6-FTZ:C'=R`5CM[<\W<]AX+\VS4X^SL
MTS7#P_UGH,W;&FA&^(2_HQ>7>4],U3SWYZ?6KR,BRBF$]T_["A/[J!2>IV'_
M`!+-SJ<D=-@X(_41P_\`%3>9T.&>NU7BR'H!XO\`B8/?=\YA[I__U>^^=/RN
M\G^<[FVN/,-M+=-:(R6Z+/+&BAC5CQ1E7D?YLNQ9Y0^EKGBC+F@O*WY*_EUY
M7UF/6=(TTQ:A"K)%+)+)+QYBC$*[$<J;<L.34SF*)1#!&)L,YRAM8YYT_+SR
MGYSM[:#S#9_6EM',ENRN\;J6%&')"#1NXRW%FE#Z2PGCC+FQ_1OR$_+31M5M
M=5TVPFM[^RD$MO,MS-56'L6H01LRG[662U<Y"B6$=/`&P]#S&;F/>=/(/ECS
MG96]GY@MFN;>UE]:%5D>.C\2M:H178Y9BRR@;BPGC$A12ORE^3GD'REK'Z7T
M.Q>WOO2:'U&FED'!Z%AQ=B.V3R:B<Q1+&&&,389KE#:\[U;\@/ROU75+O4[W
M39)+R]E>>X<7$RAI)#R8T#4&^9,=7D`H%HEIX$W2$_Z%M_*/_JU2?]),_P#S
M5A_.Y.]'Y6'<[_H6W\H_^K5)_P!),_\`S5C^=R=Z_E8=RO9?\X\_E79W*7-O
MIDBS1UXM]8F/44Z%LE'7Y0;!:\N@Q9(F,AL62?\`*NO*1T3]"M9<K%9&EC#,
MQ='?JR.3R7(_G<O'QWZFO^2\'A>%P^A(8OR.\G)/ZC274D=:^D9`!\B0H;,H
M]KYJ_A<`>SFF!OU?-FND:+I>CV:V>FVZ6ULN_!!U/<L3NS>YS7Y<LLAN1XB[
MG!@ABCPP'#%`^8_)F@>8F@;5H&F-L&$5'9*<Z<OLD>&68-5/%?":MIU>@Q:B
MO$'%PIK96<%G:0VD`XPP(L42DDT5!Q45/L,HE(DDGF7*A`1B(CE'9(O,GY?^
M5_,+^M?VO&ZI3ZU"?3E('B1LW^R&9.#6Y,7TG;^:X.K[,P9]YQ]7\X?4D-M^
M2'DV*0/*UU.`:^F\@"GY\54_CF5+M?,>5!P8>SNF!L\4OBSC3=,T_3+1+.PM
MTMK:/[,48H/G[GWS73R2F;D;+NL6*../#$<,43D&Q__6]4XJ[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7__7]4XJ[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7__0]4XJ[%78J[%78J[%
A78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
